Cantor Fitzgerald Weighs in on Alumis FY2025 Earnings

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Alumis in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings per share of ($4.13) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.15) per share.

Several other research firms have also issued reports on ALMS. HC Wainwright restated a “buy” rating and set a $26.00 price target on shares of Alumis in a research report on Monday, January 6th. Baird R W raised Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. Finally, Robert W. Baird began coverage on Alumis in a research report on Thursday, October 31st. They set an “outperform” rating and a $25.00 price target on the stock. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Alumis presently has an average rating of “Buy” and a consensus target price of $26.83.

Alumis Stock Up 1.7 %

Shares of Alumis stock opened at $6.68 on Thursday. The company has a fifty day moving average of $8.33 and a 200-day moving average of $10.56. Alumis has a 52-week low of $6.40 and a 52-week high of $13.53.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ALMS. BNP Paribas Financial Markets bought a new stake in shares of Alumis in the 3rd quarter worth approximately $27,000. China Universal Asset Management Co. Ltd. purchased a new stake in Alumis in the fourth quarter worth $79,000. MetLife Investment Management LLC bought a new stake in Alumis in the third quarter valued at $89,000. JPMorgan Chase & Co. purchased a new position in Alumis during the 3rd quarter valued at $191,000. Finally, Barclays PLC bought a new position in Alumis in the 3rd quarter worth $197,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.